{
    "organizations": [],
    "uuid": "f49eb4f8244a6251236b6037433e0fd0b5da5b02",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/06/pr-newswire-neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2017-financial-results.html",
    "ord_in_thread": 0,
    "title": "Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2017 financial results after the Nasdaq market closes on Tuesday, Feb. 13, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).\nParticipants can access the live conference call by dialing 888-632-3389 (US) or 785-424-1673 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine's website under Investors at http://www.neurocrine.com . A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.\nAbout Neurocrine Biosciences, Inc.\nNeurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company markets INGREZZA Â® (valbenazine) capsules in the United States for the treatment of adults with tardive dyskinesia. INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first FDA approved product indicated for the treatment of adults with tardive dyskinesia. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.\nNeurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com .\nView original content: http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2017-financial-results-300593725.html\nSOURCE Neurocrine Biosciences, Inc.",
    "published": "2018-02-06T21:15:00.000+02:00",
    "crawled": "2018-02-06T23:39:06.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "san",
        "diego",
        "neurocrine",
        "bioscience",
        "nasdaq",
        "nbix",
        "announced",
        "today",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "nasdaq",
        "market",
        "close",
        "tuesday",
        "neurocrine",
        "host",
        "conference",
        "call",
        "webcast",
        "discus",
        "financial",
        "result",
        "provide",
        "company",
        "update",
        "day",
        "pacific",
        "time",
        "eastern",
        "time",
        "participant",
        "access",
        "live",
        "conference",
        "call",
        "dialing",
        "u",
        "international",
        "using",
        "conference",
        "id",
        "nbix",
        "webcast",
        "also",
        "accessed",
        "neurocrine",
        "website",
        "investor",
        "http",
        "replay",
        "webcast",
        "available",
        "website",
        "approximately",
        "one",
        "hour",
        "conclusion",
        "event",
        "archived",
        "one",
        "month",
        "neurocrine",
        "bioscience",
        "neurocrine",
        "bioscience",
        "san",
        "diego",
        "based",
        "biotechnology",
        "company",
        "focused",
        "neurologic",
        "psychiatric",
        "endocrine",
        "related",
        "disorder",
        "company",
        "market",
        "ingrezza",
        "valbenazine",
        "capsule",
        "united",
        "state",
        "treatment",
        "adult",
        "tardive",
        "dyskinesia",
        "ingrezza",
        "novel",
        "selective",
        "vesicular",
        "monoamine",
        "transporter",
        "vmat2",
        "inhibitor",
        "first",
        "fda",
        "approved",
        "product",
        "indicated",
        "treatment",
        "adult",
        "tardive",
        "dyskinesia",
        "company",
        "three",
        "clinical",
        "program",
        "elagolix",
        "hormone",
        "antagonist",
        "woman",
        "health",
        "partnered",
        "abbvie",
        "opicapone",
        "novel",
        "inhibitor",
        "investigation",
        "adjunct",
        "therapy",
        "levodopa",
        "parkinson",
        "patient",
        "ingrezza",
        "novel",
        "selective",
        "vmat2",
        "inhibitor",
        "investigation",
        "treatment",
        "tourette",
        "syndrome",
        "neurocrine",
        "bioscience",
        "news",
        "release",
        "available",
        "company",
        "website",
        "via",
        "internet",
        "http",
        "view",
        "original",
        "content",
        "http",
        "source",
        "neurocrine",
        "bioscience",
        "inc"
    ]
}